Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 2
2007 2
2009 2
2010 2
2011 2
2012 4
2013 4
2014 4
2015 4
2017 1
2018 1
2019 1
2020 2
2021 1
2022 3
2023 3
2024 3
2025 5
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ii de[au] (746 results)?
Gene Therapy in Amyotrophic Lateral Sclerosis.
Fang T, Je G, Pacut P, Keyhanian K, Gao J, Ghasemi M. Fang T, et al. Among authors: je g. Cells. 2022 Jun 29;11(13):2066. doi: 10.3390/cells11132066. Cells. 2022. PMID: 35805149 Free PMC article. Review.
It includes four major strategies: (i) removal or inhibition of abnormal transcribed RNA using microRNA or antisense oligonucleotides (ASOs), (ii) degradation of abnormal mRNA using RNA interference (RNAi), (iii) decrease or inhibition of mutant proteins (e.g., using antib …
It includes four major strategies: (i) removal or inhibition of abnormal transcribed RNA using microRNA or antisense oligonucleotides (ASOs) …
Genipin derivative induced the apoptosis and inhibited the invasion and migration of A549 cancer cells via regulation of EGFR/JAK1/STAT3 signaling.
Kim DH, Hwang HH, Hong J, Seo K, Choi JH, Je JH, Lee HC, Yoo JS, Ko SG, Lee JY. Kim DH, et al. Among authors: je jh. Bioorg Med Chem Lett. 2025 Dec 1;128:130320. doi: 10.1016/j.bmcl.2025.130320. Epub 2025 Jun 29. Bioorg Med Chem Lett. 2025. PMID: 40592362
Notably, although 2b did not inhibit ATP-dependent EGFR kinase activity in vitro, molecular docking simulations indicated its binding to the EGFR extracellular domain (domain III), suggesting an alternative, ATP-independent mechanism-likely via interference with EGF bindin …
Notably, although 2b did not inhibit ATP-dependent EGFR kinase activity in vitro, molecular docking simulations indicated its binding to the …
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Ghatalia P, et al. Among authors: je y. Crit Rev Oncol Hematol. 2015 May;94(2):228-37. doi: 10.1016/j.critrevonc.2014.12.008. Epub 2014 Dec 19. Crit Rev Oncol Hematol. 2015. PMID: 25577572
A total of 10,647 patients from 16 phase III trials and 5 phase II trials were selected. All grade CHF occurred in 138 of 5752 (2.39%) patients receiving VEGFR TKIs and 37 of 4895 (0.75%) patients in the non-TKI group. ...
A total of 10,647 patients from 16 phase III trials and 5 phase II trials were selected. All grade CHF occurred in 138 of 5752 (2.39% …
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. Ghatalia P, et al. Among authors: je y. Br J Cancer. 2015 Jan 20;112(2):296-305. doi: 10.1038/bjc.2014.564. Epub 2014 Nov 6. Br J Cancer. 2015. PMID: 25349964 Free PMC article.
METHODS: We conducted a trial-level meta-analysis of randomised phase II and III trials comparing arms with and without a US Food and Drug Administration-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, axitinib, vandetanib, cabozantinib, ponatinib and regorafenib). .. …
METHODS: We conducted a trial-level meta-analysis of randomised phase II and III trials comparing arms with and without a US Food and …
Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials.
Ghatalia P, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Ghatalia P, et al. Among authors: je y. Crit Rev Oncol Hematol. 2015 Aug;95(2):251-63. doi: 10.1016/j.critrevonc.2015.03.006. Epub 2015 Apr 9. Crit Rev Oncol Hematol. 2015. PMID: 25900071 Review.
A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascula …
A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was con …
Surgical Outcomes of Cardiac Myxoma Resection Through Right Mini-Thoracotomy.
Shin C, Ju MH, Lee CH, Lim MH, Je HG. Shin C, et al. Among authors: je hg. J Chest Surg. 2023 Jan 5;56(1):42-48. doi: 10.5090/jcs.22.094. Epub 2022 Dec 15. J Chest Surg. 2023. PMID: 36517950 Free PMC article.
RESULTS: Thirteen patients (20.3%) had a history of preoperative stroke, and 7 (11.7%) had dyspnea with New York Heart Association functional class III or IV. Sixty-one cases (95.3%) had myxomas in the left atrium. The mean cardiopulmonary bypass and cardiac ischemic times …
RESULTS: Thirteen patients (20.3%) had a history of preoperative stroke, and 7 (11.7%) had dyspnea with New York Heart Association functiona …
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Choueiri TK, et al. Among authors: je y. J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. J Clin Oncol. 2010. PMID: 20351323
PATIENTS AND METHODS: PubMed databases were searched for articles published from January 1966 to July 2009, and abstracts presented at the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) meetings held between 2004 and 2009 were sea …
PATIENTS AND METHODS: PubMed databases were searched for articles published from January 1966 to July 2009, and abstracts presented at the A …
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK. Richards CJ, et al. Among authors: je y. J Clin Oncol. 2011 Sep 1;29(25):3450-6. doi: 10.1200/JCO.2010.34.4309. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810682
Eligible studies were limited to phase II and III trials of sunitinib with adequate safety reporting in patients with cancer of any tumor type. ...
Eligible studies were limited to phase II and III trials of sunitinib with adequate safety reporting in patients with cancer of any t …
Immune activation of apolipophorin-III and its distribution in hemocyte from Hyphantria cunea.
Kim HJ, Je HJ, Park SY, Lee IH, Jin BR, Yun HK, Yun CY, Han YS, Kang YJ, Seo SJ. Kim HJ, et al. Among authors: je hj. Insect Biochem Mol Biol. 2004 Oct;34(10):1011-23. doi: 10.1016/j.ibmb.2004.05.005. Insect Biochem Mol Biol. 2004. PMID: 15475296
Apolipophorin-III (apoLp-III) is a hemolymph protein whose function is to facilitate lipid transport in an aqueous medium. ...We identified the cDNA sequence of Hyphantria cunea apoLp-III by oligonucleotide-primed amplification, and 5'- and 3'-RACE PCR. Since …
Apolipophorin-III (apoLp-III) is a hemolymph protein whose function is to facilitate lipid transport in an aqueous medium. ... …
39 results